In EGFRvIII (an oncogenic form of epidermal growth factor receptor)-driven glioma cells, the expression of PDPN was found to be under negative regulation by the chromatin modifier enhancer of zeste homolog 2 (EZH2). Here, PDPN is linked to central nervous system cancer.